Drug treatments for adjuvant chemotherapy in breast cancer: Recent trials and future directions Journal Article
| Author: | Dang, C. T. |
| Article Title: | Drug treatments for adjuvant chemotherapy in breast cancer: Recent trials and future directions |
| Abstract: | Adjuvant chemotherapy with anthracycline-based regimens has been proven to decrease the risk of relapse and cancer-related mortality in women with early-stage breast cancer. The taxanes, paclitaxel and docetaxel, have been incorporated into several adjuvant chemotherapy regimens in recent studies. Some of these trials have matured and demonstrated a definitive benefit with the use of taxanes. The available studies reveal that the addition of a taxane after an anthracycline or the substitution of a taxane into a three-drug regimen, such as docetaxel, doxorubicin and cyclophosphamide, clearly demonstrate a benefit for taxanes in the adjuvant treatment of breast cancer. The toxicities of the taxanes are generally acceptable. Targeted therapy, such as with trastuzumab, has demonstrated a large benefit that previously has never been seen in adjuvant chemotherapy trials, and thus, should now be part of the standard in the treatment of HER-2/neu positive breast cancer. Newer agents are on the horizon. © 2006 Future Drugs Ltd. |
| Keywords: | treatment outcome; overall survival; clinical trial; review; doxorubicin; fluorouracil; cancer combination chemotherapy; drug targeting; paclitaxel; cancer adjuvant therapy; cancer radiotherapy; disease free survival; chemotherapy, adjuvant; chemotherapy; treatment; methotrexate; cancer staging; antineoplastic agent; breast cancer; anemia; mastectomy; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; antineoplastic agents, phytogenic; cyclophosphamide; breast neoplasms; cancer mortality; docetaxel; febrile neutropenia; adjuvant chemotherapy; breast tumor; partial mastectomy; tamoxifen; cancer relapse; epirubicin; taxoids; taxane derivative; anthracycline derivative; estrogen receptor; progesterone receptor; trastuzumab; recombinant granulocyte colony stimulating factor; risk reduction; erythrocyte transfusion; granulocyte colony stimulating factor; clinical trials; hematologic disease; taxoid; adjuvant |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 6 |
| Issue: | 3 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2006-03-01 |
| Start Page: | 427 |
| End Page: | 436 |
| Language: | English |
| DOI: | 10.1586/14737140.6.3.427 |
| PUBMED: | 16503859 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 5" - "Export Date: 4 June 2012" - "CODEN: ERATB" - "Source: Scopus" |
